Publication:
Characterisation of retrotransposon insertion polymorphisms in whole genome sequencing data from individuals with amyotrophic lateral sclerosis.

dc.contributor.authorSavage, Abigail L
dc.contributor.authorIacoangeli, Alfredo
dc.contributor.authorSchumann, Gerald G
dc.contributor.authorRubio-Roldan, Alejandro
dc.contributor.authorGarcia-Perez, Jose L
dc.contributor.authorAl Khleifat, Ahmad
dc.contributor.authorKoks, Sulev
dc.contributor.authorBubb, Vivien J
dc.contributor.authorAl-Chalabi, Ammar
dc.contributor.authorQuinn, John P
dc.date.accessioned2023-05-03T15:00:31Z
dc.date.available2023-05-03T15:00:31Z
dc.date.issued2022-08-10
dc.description.abstractThe genetics of an individual is a crucial factor in understanding the risk of developing the neurodegenerative disease amyotrophic lateral sclerosis (ALS). There is still a large proportion of the heritability of ALS, particularly in sporadic cases, to be understood. Among others, active transposable elements drive inter-individual variability, and in humans long interspersed element 1 (LINE1, L1), Alu and SINE-VNTR-Alu (SVA) retrotransposons are a source of polymorphic insertions in the population. We undertook a pilot study to characterise the landscape of non-reference retrotransposon insertion polymorphisms (non-ref RIPs) in 15 control and 15 ALS individuals' whole genomes from Project MinE, an international project to identify potential genetic causes of ALS. The combination of two bioinformatics tools (mobile element locator tool (MELT) and TEBreak) identified on average 1250 Alu, 232 L1 and 77 SVA non-ref RIPs per genome across the 30 analysed. Further PCR validation of individual polymorphic retrotransposon insertions showed a similar level of accuracy for MELT and TEBreak. Our preliminary study did not identify a specific RIP or a significant difference in the total number of non-ref RIPs in ALS compared to control genomes. The use of multiple bioinformatic tools improved the accuracy of non-ref RIP detection and our study highlights the potential importance of studying these elements further in ALS.
dc.identifier.doi10.1016/j.gene.2022.146799
dc.identifier.essn1879-0038
dc.identifier.pmid35963498
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.gene.2022.146799
dc.identifier.urihttp://hdl.handle.net/10668/22249
dc.journal.titleGene
dc.journal.titleabbreviationGene
dc.language.isoen
dc.organizationCentro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica-GENYO
dc.page.number146799
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAlu
dc.subjectAmyotrophic lateral sclerosis
dc.subjectLINE-1
dc.subjectPolymorphism
dc.subjectRetrotransposon
dc.subjectSVA
dc.subjectWhole genome sequencing
dc.subject.meshAmyotrophic Lateral Sclerosis
dc.subject.meshHumans
dc.subject.meshLong Interspersed Nucleotide Elements
dc.subject.meshNeurodegenerative Diseases
dc.subject.meshPilot Projects
dc.subject.meshRetroelements
dc.subject.meshWhole Genome Sequencing
dc.titleCharacterisation of retrotransposon insertion polymorphisms in whole genome sequencing data from individuals with amyotrophic lateral sclerosis.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number843
dspace.entity.typePublication

Files